Dr. Siefker-Radtke on Advancements in Small Cell Urothelial Cancer
Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses treatment advancements in small cell urothelial cancer.
Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses treatment advancements in small cell urothelial cancer.
Small cell urothelial cancer is a rare type of bladder cancer that occurs in approximately 1% of patients. Historically, outcomes have been very poor, adds Siefker-Radtke, with 5-year survival rates between 20% and 30%.
Recent studies have investigated possible treatments for this cancer, Siefker-Radtke explains. For example, if the disease can be treated upfront with neoadjuvant chemotherapy, long-term survival rates can be significantly improved to approximately 70% to 80%.
<<<
